Alan Russell's most recent trade in Edgewise Therapeutics Inc was a trade of 100,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2025 | 100,000 | 1,247,365 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.60 per share. | 26 Aug 2025 | 100,000 | 23,400 | - | 14.6 | 1,459,760 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 26 Aug 2025 | 100,000 | 123,400 | - | 0.2 | 18,000 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2025 | 168,750 | 168,750 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2025 | 28,125 | 28,125 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 5,781 | 25,307 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 5,781 | 17,344 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.39 per share. | 12 Aug 2025 | 1,907 | 23,400 | - | 13.4 | 25,539 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 5,209 | 20,072 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 5,209 | 0 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 01 May 2025 | 1,551 | 18,521 | - | 16.5 | 25,520 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.02 per share. | 07 Mar 2025 | 200 | 14,863 | - | 30.0 | 6,004 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 200 | 1,456,580 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 07 Mar 2025 | 200 | 15,063 | - | 0.2 | 36 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 8,015 | 1,348,765 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 05 Feb 2025 | 8,015 | 22,878 | - | 0.2 | 1,443 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.02 per share. | 05 Feb 2025 | 8,015 | 14,863 | - | 30.0 | 240,623 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 05 Feb 2025 | 1,200 | 16,063 | - | 0.2 | 216 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.13 per share. | 05 Feb 2025 | 1,200 | 14,863 | - | 30.1 | 36,153 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 1,200 | 1,347,565 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 30 Dec 2024 | 100,000 | 114,863 | - | 0.2 | 18,000 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.37 per share. | 30 Dec 2024 | 100,000 | 14,863 | - | 27.4 | 2,737,470 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 100,000 | 1,356,780 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 75,000 | 1,456,780 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 20 Sep 2024 | 75,000 | 87,719 | - | 0.2 | 13,500 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.25 per share. | 20 Sep 2024 | 74,185 | 13,534 | - | 28.3 | 2,096,053 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.51 per share. | 20 Sep 2024 | 815 | 12,719 | - | 29.5 | 24,049 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 138,750 | 138,750 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 23,125 | 23,125 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 5,208 | 8,814 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 5,208 | 5,209 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.91 per share. | 01 May 2024 | 1,576 | 7,238 | - | 18.9 | 29,802 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.33 per share. | 26 Dec 2023 | 172,585 | 3,606 | - | 9.3 | 1,610,097 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 5,208 | 177,793 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 5,208 | 10,417 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.91 per share. | 01 May 2023 | 1,602 | 176,191 | - | 8.9 | 14,266 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 15,625 | 15,625 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 30 Nov 2021 | 147,585 | 147,585 | - | 0.2 | 26,565 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 147,585 | 0 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 25,000 | 130,352 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 30 Nov 2021 | 25,000 | 172,585 | - | 0.5 | 11,250 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.07 per share. | 15 Nov 2021 | 441 | 38 | - | 19.1 | 8,410 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.61 per share. | 15 Nov 2021 | 38 | 0 | - | 19.6 | 745 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.94 per share. | 09 Nov 2021 | 16,864 | 53,355 | - | 19.9 | 336,275 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.82 per share. | 09 Nov 2021 | 15,595 | 12,722 | - | 19.8 | 309,043 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 09 Nov 2021 | 12,712 | 40,643 | - | 20.3 | 258,031 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.70 per share. | 09 Nov 2021 | 11,746 | 28,897 | - | 19.7 | 231,447 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.51 per share. | 09 Nov 2021 | 8,562 | 479 | - | 19.5 | 167,074 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.43 per share. | 09 Nov 2021 | 3,681 | 9,041 | - | 20.4 | 75,195 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.21 per share. | 09 Nov 2021 | 580 | 28,317 | - | 20.2 | 11,723 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.62 per share. | 04 Nov 2021 | 13,036 | 79,236 | - | 19.6 | 255,783 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.16 per share. | 04 Nov 2021 | 9,017 | 70,219 | - | 20.2 | 181,824 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.76 per share. | 04 Nov 2021 | 7,392 | 92,278 | - | 19.8 | 146,092 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.67 per share. | 04 Nov 2021 | 6 | 92,272 | - | 20.7 | 124 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.98 per share. | 01 Nov 2021 | 20,822 | 105,032 | - | 18.0 | 374,425 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.43 per share. | 01 Nov 2021 | 17,519 | 125,854 | - | 17.4 | 305,360 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.84 per share. | 01 Nov 2021 | 4,243 | 100,789 | - | 18.8 | 79,944 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.42 per share. | 01 Nov 2021 | 1,119 | 99,670 | - | 19.4 | 21,726 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 01 Nov 2021 | 469 | 143,373 | - | 18.0 | 8,454 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.18 per share. | 14 Oct 2021 | 5,749 | 145,275 | - | 18.2 | 104,517 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.13 per share. | 14 Oct 2021 | 1,307 | 143,968 | - | 18.1 | 23,698 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 14 Oct 2021 | 126 | 143,842 | - | 18 | 2,268 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.02 per share. | 11 Oct 2021 | 1,270 | 151,024 | - | 18.0 | 22,885 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.56 per share. | 06 Oct 2021 | 13,018 | 158,196 | - | 18.6 | 241,614 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 06 Oct 2021 | 5,902 | 152,294 | - | 18.1 | 107,121 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 06 Oct 2021 | 2,108 | 171,214 | - | 18.0 | 38,007 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.26 per share. | 01 Oct 2021 | 5,404 | 173,322 | - | 18.3 | 98,677 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 01 Oct 2021 | 274 | 178,826 | - | 18 | 4,932 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 01 Oct 2021 | 100 | 178,726 | - | 18 | 1,800 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.30 per share. | 28 Sep 2021 | 14,610 | 190,944 | - | 17.3 | 252,753 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 28 Sep 2021 | 11,226 | 179,718 | - | 16.8 | 188,934 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.47 per share. | 28 Sep 2021 | 618 | 179,100 | - | 17.5 | 10,796 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.34 per share. | 23 Sep 2021 | 21,763 | 242,337 | - | 18.3 | 399,133 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 23 Sep 2021 | 20,100 | 217,165 | - | 18.2 | 365,016 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.98 per share. | 23 Sep 2021 | 11,594 | 205,571 | - | 18.0 | 208,460 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.42 per share. | 23 Sep 2021 | 5,072 | 237,265 | - | 19.4 | 98,498 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.47 per share. | 23 Sep 2021 | 17 | 205,554 | - | 18.5 | 314 | Common Stock |
| Edgewise Therapeutics Inc | Alan Russell | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) |